🔍 Observations
Topline
- Revenue from operations grew 19.1% YoY (₹7,02,846L → ₹8,37,345L), compounding on a large base — scale is not diluting growth velocity.
- Q4FY26 revenue at ₹2,14,289L grew 12.2% YoY (vs ₹1,90,974L Q4FY25) and 3.6% QoQ — sequential momentum intact.
- No segment data provided, but the pace of capacity addition (PPE up ₹1,49,712L YoY) signals the topline engine is being actively fuelled.
Bottomline
- PAT grew 34.1% YoY (₹1,07,588L → ₹1,44,241L) — bottomline growing nearly 1.8x faster than revenue, confirming strong operating leverage.
- Effective tax rate dropped sharply: 23.5% in FY26 vs 23.5% in FY25 headline-level, but FY25 included a deferred tax credit (₹562L) vs FY26 deferred charge (₹2,186L), masking an underlying cash tax improvement.
- Q4FY26 PAT at ₹34,222L grew 7.3% YoY (vs ₹31,900L Q4FY25) — solid, though Q4FY25 had a higher current tax outflow (₹7,213L vs ₹5,858L), flattering the comparison.
Margins
- EBITDA proxy (PBT before exceptional + D&A + Finance costs): FY26 = ₹1,72,382L + ₹44,653L + ₹23,510L = ₹2,40,545L on revenue of ₹8,37,345L → EBITDA margin ~28.7% vs FY25: (₹1,48,000L + ₹35,942L + ₹16,502L) / ₹7,02,846L = ₹2,00,444L → ~28.5% — margins essentially flat despite revenue scale-up.
- Net profit margin: ₹1,44,241L / ₹8,37,345L = 17.2% vs ₹1,07,588L / ₹7,02,846L = 15.3% — 190bps expansion, driven by operating leverage on fixed costs.
- Finance costs surged 42.5% YoY (₹16,502L → ₹23,510L), partially offsetting operating gains; bears watching as debt expands with capex.
Growth Trajectory
- Revenue CAGR implied over FY25–26 at 19.1% on a ₹700Cr+ base is exceptional for a hospital network — pricing power + volume both contributing.
- PAT growing at 34% with EBITDA flat suggests the leverage point is below EBITDA: D&A and finance costs are scaling, but PBT-to-PAT conversion is improving.
- Capacity buildout (CWIP conversion + fresh PPE additions) suggests FY27 will test whether new beds can ramp revenues fast enough to sustain margin trajectory.
🧮 Profit & Loss Statement
🧮 Balance Sheet
🧮 Cash Flows Statement
🟢 Green Flags
- 34% PAT growth on 19% revenue growth — operating leverage is structurally real, not one-off.
- OCF at ₹1,63,332L, up from ₹1,43,796L — cash earnings quality is high; the business generates cash, not just accounting profit.
- Net profit margin expanded 190bps to 17.2% — rare for a capital-heavy hospital network at this scale.
- Equity base growing organically: Reserves up ₹1,36,477L YoY purely from retained earnings — no dilutive equity issuances.
- PPE up ₹1,49,712L YoY — aggressive capacity addition signals management confidence in demand visibility.
- EPS grew 33.9% (Basic: ₹11.07 → ₹14.83) with minimal share dilution — per-share value creation is intact.
- OCF covers capex at ₹1,63,332L vs ₹1,48,453L capex spend — investments are largely self-funded; limited equity dilution risk.
🔴 Red Flags
- Trade receivables surged 41.1% (₹68,731L → ₹96,975L) against 19.1% revenue growth — receivables are growing 2x faster than sales; collection cycle is lengthening.
- Short-term borrowings nearly doubled (₹21,877L → ₹46,816L) — signals working capital stress being plugged with debt.
- Finance costs up 42.5% YoY — outpacing revenue growth; further debt-funded capex could compress PBT margins.
- Loans to healthcare service providers up ₹36,300L net (₹38,345L → ₹74,645L) — off-balance-sheet exposure via inter-company lending; recoverability risk if associates underperform.
- Free cash flow is barely positive: OCF ₹1,63,332L minus capex ₹1,48,453L = FCF of ~₹14,879L — near-zero FCF despite strong PAT; limited buffer for unexpected capex or working capital shocks.
- Deferred tax liability growing (₹64,819L → ₹68,753L) — future cash tax outflows are building; effective cash tax rate may rise.
- Impairment on trade receivables jumped (₹2,506L → ₹4,716L) — receivable quality deteriorating in tandem with the volume build-up.
📊 Balance Sheet Analysis
- Leverage is moderate but rising: Total borrowings (current + non-current) = ₹2,43,866L + ₹46,816L = ₹2,90,682L vs FY25 ₹2,48,883L — debt up ₹41,799L YoY; debt-to-equity at 0.27x, still manageable.
- Asset quality is goodwill-heavy: Goodwill + intangibles = ₹6,00,644L, representing 34.9% of total assets — any impairment here would significantly dent net worth.
- Liquidity is adequate but tight: Current ratio = ₹1,94,479L / ₹2,18,694L = 0.89x — sub-1 current ratio means current liabilities exceed current assets; reliant on OCF to bridge.
- Equity-financed growth: Debt-to-equity at 0.27x and total equity of ₹10,74,663L provide a strong buffer; balance sheet retains room for further leverage if needed.
💰 Cash Flow Analysis
- OCF at ₹1,63,332L is clean and growing (vs ₹1,43,796L FY25) — the hospital’s core operations are a reliable cash engine.
- Investing outflows of ₹1,68,899L almost entirely consumed by PPE addition (₹1,48,453L) and healthcare loans (₹42,000L gross) — the business is in intensive investment mode.
- FCF of ~₹14,879L (OCF minus capex) is thin; dividend of ₹14,562L nearly consumed all of it — payout discipline will need to flex as capex scales.
- Financing activities generated a net ₹5,927L — borrowing (₹53,929L) offset by repayments and finance costs; debt funding capex gap is modest this year but compounding.
💡 Investment Outlook
Max Healthcare’s FY26 results confirm a hospital network at an inflection point — 19% revenue growth and 34% PAT growth on a ₹700Cr+ revenue base is not easy to sustain, yet the operational leverage is clearly in motion.
The near-zero FCF and deteriorating receivables are the two live stress points to watch: if new capacity ramps slower than expected, debt servicing will pressure margins.
The structural re-rating case remains intact — margin expansion, strong OCF, and minimal dilution — but investors should track receivable days and debt-to-EBITDA quarterly as the capex cycle peaks in FY27.
Disclaimer: This post features ChartAlert-AI-generated financial content which may contain inaccuracies or errors. This commentary is strictly for informational purposes and does not constitute a recommendation to buy or sell any security. Investors are responsible for performing their own due diligence; always consult with a licensed financial advisor before making investment decisions.
Beyond the Price Action: Fundamental Analysis is Coming to ChartAlert
ChartAlert is evolving into integrated research with a future update that will embed fundamental data into your workflow. Alongside technical analysis, the new release will allow access to financial data, quarterly results review, earnings call transcripts, and valuation tools, connecting price action with corporate performance for smarter, data‑driven decisions.